<DOC>
	<DOCNO>NCT01858272</DOCNO>
	<brief_summary>The primary objective study evaluate efficacy , dose , safety intra-ulcer injection H5.020CMV.PDGF-b adult venous leg ulcer . The primary endpoint Phase I trial determination Maximum Tolerated Dose ( MTD ) intra-ulcer injection H5.020CMV.PDGF-b .</brief_summary>
	<brief_title>Preliminary Testing New Treatment Chronic Leg Wounds</brief_title>
	<detailed_description />
	<mesh_term>Varicose Ulcer</mesh_term>
	<mesh_term>Platelet-derived growth factor BB</mesh_term>
	<criteria>1 . Subject must examination study investigator consistent venous leg ulcer ( i.e. , varicose vein , venous blush , wound gaiter area leg , dermatitis , lipodermatosclerosis ) . 2 . Subject must receive limb compression therapy least 6 week without improvement wound size . 3 . The size study wind must large 5 small 60 cm2 measure acetate trace planimetry . 4 . By patient history , study wind must six month old . 5 . For subject one wound meet requirement 2 3 , one wound randomly select treated H5.020CMV.PDGFb . 6 . By history , subject must able tolerate limb compression bandage . 7 . Ankle brachial index ( ABI ) great equal 0.85 8 . White blood cell count great equal 3500/mm3 , platelet &lt; 1,000,000/mm3 great 100,000/mm3 hemoglobin &gt; 10.0 g % . 9 . Signed informed consent 10 . Subject age must great equal 18 year age . In reality , would unlikely anyone less 45 year old venous leg ulcer . 1 . Subject active cancer nonmelanomatous skin cancer . If cancer remission , subject exclude unless remission extend least 10 year . 2 . Subjects life expectancy le 6 month . 3 . Liver function test ( Alamine Amino Trandferase , ALT ; angiotensin sensitivity test , AST ; alkaline phosphatase ALK PHOS , bilirubin ) great 1.5x upper limit normal reference lab . 4 . Sedimentation rate ( ESR ) baseline great 60 . 5 . A Rheumatoid Factor baseline great 30 IU/ml ( Less 30 IU/ml consider negative 30 80IU/ml consider weakly positive University Pennsylvania Pathology Laboratories criterion use March 2007 ) . 6 . Anti Nuclear Antibody test dilutional titer great 1:160 ( Less 1:160 consider negative University Pennsylvania Pathology Laboratories criterion use March 2007 ) 7 . Patients intercurrent organ damage , abnormal laboratory test , medical problem opinion PI jeopardize ability participate study heal wound . 8 . Any subject recognize rheumatic disease ( e.g. , lupus , scleroderma , dermatomyositis , rheumatoid arthritis , polymyalgia , etc . ) exclude study 9 . Pregnant lactating female . A pregnancy test perform fertile premenopausal female prior entry study . Treatment may begin result pretreatment pregnancy test ascertain . 10 . Any requirement systemic corticosteroid immunosuppressive , history corticosteroid immunosuppressive use 4 week previous study entry . 11 . Seropositive hepatitis B C surface antigen . 12 . Patient refusal use inability successfully use limb compression bandage change weekly . 13 . Any concurrent medical illness exacerbate H5.020CMV.PDGFb administration .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2017</verification_date>
</DOC>